Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Renier J Brentjens

Showing results (1-10 of 128) with videos related to

Pageof 13
Sort By:
Clinical Advances in Hematology & Oncology : H&O|April 9, 2016
Are chimeric antigen receptor T cells ready for prime time?Renier J Brentjens
Current Hematology Reports|December 22, 2004
Novel approaches to immunotherapy for B-cell malignanciesRenier J Brentjens
Current Hematologic Malignancy Reports|April 29, 2010
Novel approaches to the immunotherapy of B-cell malignancies: An updateRenier J Brentjens
Current Opinion in Molecular Therapeutics|August 4, 2009
Cellular therapies in acute lymphoblastic leukemiaRenier J Brentjens
Current Oncology Reports|August 5, 2004
Novel approaches to immunotherapy for B-cell malignanciesRenier J Brentjens
Blood|April 28, 2012
CARs and cancers: questions and answersRenier J Brentjens
Expert Review of Hematology|May 4, 2016
Medical management of side effects related to CAR T cell therapy in hematologic malignanciesManjusha Namuduri, Renier J Brentjens
Expert Review of Hematology|April 9, 2020
Enhancing CAR T cell efficacy: the next step toward a clinical revolution?Manjusha Namuduri, Renier J Brentjens
Nature Medicine|October 10, 2018
Tumors evading CARs-the chase is onSarwish Rafiq, Renier J Brentjens
Advances in Pharmacology (San Diego, Calif.)|October 7, 2004
Somatic cell engineering and the immunotherapy of leukemias and lymphomasRenier J Brentjens, Michel Sadelain
Pageof 13

Showing results (1-10 of 128) with videos related to

Sort By:
Pageof 13
Clinical Advances in Hematology & Oncology : H&O|April 9, 2016
Are chimeric antigen receptor T cells ready for prime time?Renier J Brentjens
Current Hematology Reports|December 22, 2004
Novel approaches to immunotherapy for B-cell malignanciesRenier J Brentjens
Current Hematologic Malignancy Reports|April 29, 2010
Novel approaches to the immunotherapy of B-cell malignancies: An updateRenier J Brentjens
Current Opinion in Molecular Therapeutics|August 4, 2009
Cellular therapies in acute lymphoblastic leukemiaRenier J Brentjens
Current Oncology Reports|August 5, 2004
Novel approaches to immunotherapy for B-cell malignanciesRenier J Brentjens
Blood|April 28, 2012
CARs and cancers: questions and answersRenier J Brentjens
Expert Review of Hematology|May 4, 2016
Medical management of side effects related to CAR T cell therapy in hematologic malignanciesManjusha Namuduri, Renier J Brentjens
Expert Review of Hematology|April 9, 2020
Enhancing CAR T cell efficacy: the next step toward a clinical revolution?Manjusha Namuduri, Renier J Brentjens
Nature Medicine|October 10, 2018
Tumors evading CARs-the chase is onSarwish Rafiq, Renier J Brentjens
Advances in Pharmacology (San Diego, Calif.)|October 7, 2004
Somatic cell engineering and the immunotherapy of leukemias and lymphomasRenier J Brentjens, Michel Sadelain
Pageof 13